英文名稱
VNL7-VNL5 (Venetoclax Dimer Impurity 2)
2-((1H-吡咯并[2,3-b]吡啶-5-基)氧基)-N-(4-(N-(2-((1H-吡咯并[2,3-b]吡啶-5-基)氧基)-4-(4-((4'-氯-5,5-二甲基-3,4,5,6-四氫-[1,1'-聯苯]-2-基)甲基)哌嗪- 1-基)苯甲酰基)氨磺酰基)-2-硝基苯基)-4-(4-((4'-氯-5,5-二甲基-3,4,5,6-四氫-[1,1'-聯苯] -2-基)甲基)哌嗪-1-基)-N-((四氫-2H-吡喃-4-基)甲基)苯甲酰胺
Smiles Code
CC1(C)CCC(=C(C1)c2ccc(Cl)cc2)CN3CCN(CC3)c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c(c5)N(=O)=O)c(Oc7cnc8c(ccn8C(=O)c9ccc(cc9Oc%10cnc%11[nH]ccc%11c%10)N%12CCN(CC%13=C(CC(C)(C)CC%13)c%14ccc(Cl)cc%14)CC%12)c7)c4
Standards; Enzyme Activators and Inhibitors; Pharmaceutical/API Drug Impurities/Metabolites;
VNL7-VNL5 is an impurity of Venetoclax (A112430) a potent and selective BCL-2 inhibitor that achieves potent antitumour activity while sparing platelets. It’s practical application is to treat chronic lymphocytic leukaemic cells and estrogen receptor-positive breast cancer.